Abstract
Purchase PDF (442 K)
E-mail Article
Add to my Quick Links
Cited By in Scopus (0)
Purchase PDF (44 K)
doi:10.1016/j.bmc.2008.07.022 
Copyright © 2008 Elsevier Ltd All rights reserved.
In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil
References and further reading may be available for this article. To view references and further reading you must purchase this article.
João E. Antunesa, Matheus P. Freitasa, 
, 
, Elaine F.F. da Cunhaa, Teodorico C. Ramalhoa and Roberto Rittnerb
Received 3 June 2008;
Abstract
A series of drug-like compounds derived from Sildenafil, Vardenafil and Tadalafil analogues were modelled through the MIA-QSAR (multivariate image analysis applied to quantitative structure-activity relationships) ligand-based approach. A highly predictive model was achieved and novel compounds, miscellany of substructures of these three representative phosphodiesterase type-5 (PDE-5) inhibitors were predicted using the calibration parameters obtained through partial least squares (PLS) regression. The high bioactivities of eight promising compounds were corroborated by docking evaluation. Calculated ADME–Tox (absorption, distribution, metabolism, excretion and toxicity) profiles for such compounds suggest advantages of some of them over the currently available, most common drugs used for the treatment of erectile dysfunction.
Keywords: PDE-5 inhibitors; MIA-QSAR; Docking studies; Erectile dysfunction
